Cramer Regrets Missing Regeneron Rally, Eylea 8 mg Captures 38%
Mad Money host Jim Cramer said he regretted not buying Regeneron after a JPMorgan conference meeting, noting the stock’s quiet rise from summer lows. Bayer reported its new Eylea 8 mg formulation drove 38% of total Eylea sales, underpinning Regeneron’s U.S. net product revenues from the co-developed ophthalmology drug.
1. Jim Cramer Acknowledges Missed Opportunity
Jim Cramer admitted he should have bought Regeneron shares after meeting the management at a JPMorgan conference, citing the company’s strong drug pipeline under CEO Len Schleifer and the stock’s unnoticed upward momentum from its summer lows.
2. Eylea 8 mg Boosts U.S. Revenue Streams
Bayer’s fourth-quarter report revealed that its newly launched Eylea 8 mg accounted for 38% of overall Eylea sales, which directly supports Regeneron’s U.S. net product revenues from the co-developed ophthalmology treatment and signals sustained demand.